Last reviewed · How we verify
Blood samples for DOAC measurement
This is a laboratory testing service that measures direct oral anticoagulant (DOAC) concentrations in blood samples.
This is a laboratory testing service that measures direct oral anticoagulant (DOAC) concentrations in blood samples. Used for Therapeutic drug monitoring of direct oral anticoagulants, Assessment of DOAC compliance and adherence, Perioperative management of anticoagulated patients.
At a glance
| Generic name | Blood samples for DOAC measurement |
|---|---|
| Sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
| Modality | Biologic |
| Therapeutic area | Diagnostics / Laboratory Medicine |
| Phase | FDA-approved |
Mechanism of action
Blood samples for DOAC measurement is a diagnostic service rather than a drug itself. It involves collecting and analyzing patient blood samples to quantify the plasma concentration of direct oral anticoagulants (such as apixaban, rivaroxaban, edoxaban, or dabigatran). This testing is used to assess anticoagulant levels in patients for therapeutic drug monitoring, compliance assessment, or perioperative management.
Approved indications
- Therapeutic drug monitoring of direct oral anticoagulants
- Assessment of DOAC compliance and adherence
- Perioperative management of anticoagulated patients
- Evaluation of bleeding or thrombotic events in DOAC-treated patients
Common side effects
Key clinical trials
- DOCE Study Interaction Between Direct Oral Anticoagulants and Drug-metabolizing Enzyme Inducers
- Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: